Century Therapeutics, Inc. announced that it has entered into agreement with new investor Bristol-Myers Squibb Company for issuing 2,160,760 common shares at an issue price of $23.14 per share and at a par value of $0.0001 per share for gross proceeds of $49,999,986.4 on January 7, 2022. The transaction is expected to close on January 12, 2022. The company's sale of the Shares to BMS is exempt from registration pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and corresponding provisions of state securities or “blue sky” laws, and Regulation D.